Reuters -- A 10th patient taking Biogen Idec Inc’s multiple sclerosis drug Tysabri has developed a potentially deadly brain infection since it was reintroduced to the market in July 2006.
Reuters -- A 10th patient taking Biogen Idec Inc’s multiple sclerosis drug Tysabri has developed a potentially deadly brain infection since it was reintroduced to the market in July 2006.
